Table 2.
Unadjusted and Risk-Adjusted Change in Blood Pressure (BP) and Goal Attainment Rates by Antihypertensive Therapeutic Classes Initiated as Monotherapy
| Outcomes | ACEI* (n=3,131) | Thiazide* (n=1,947) | β-blocker* (n=1,029) | ARB* (n=533) | CCB* (n=529) |
|---|---|---|---|---|---|
| Systolic, mm Hg† | |||||
| BP at index, mean (SD) | 147.6 (15.0) | 149.3 (13.4) | 147.7 (15.4) | 147.8 (14.9) | 149.5 (15.7) |
| BP at follow-up, mean (SD) | 133.6 (16.2) | 136.6 (14.9) | 134.9 (16.9) | 135.1 (15.8) | 136.7 (17.1) |
| Unadjusted change, mean (SD) | −14.0 (18.1) | −12.7 (17.1) | −12.8 (18.2) | −12.7 (17.7) | −12.8 (19.5) |
| Risk-adjusted change, mean (SD) | −13.4 (10.3) | −14.1 (9.3)‡ | −13.4 (10.8) | −13.3 (10.4) | −14.0 (10.9)§ |
| Diastolic, mm Hg† | |||||
| BP at index, mean (SD) | 90.1 (10.7) | 91.5 (10.1) | 90.1 (10.9) | 89.7 (10.4) | 89.4 (11.4) |
| BP at follow-up, mean (SD) | 81.8 (10.1) | 84.6 (10.5) | 82.8 (10.8) | 82.5 (10.5) | 82.0 (11.1) |
| Unadjusted change, mean (SD) | −8.3 (11.4)‡ | −6.8 (11.3) | −7.4 (11.3) | −7.1 (11.3) | −7.3 (11.9) |
| Risk-adjusted change, mean (SD) | −7.9 (6.6) | −8.2 (6.3)‡ | −7.7 (6.8) | −7.6 (6.4) | −7.5 (7.0) |
| Goal attainment† | |||||
| Unadjusted at goal, n (%) | 1,465 (46.8) | 826 (42.4) | 508 (49.4)¶ | 229 (43.0) | 239 (45.2) |
| Risk-adjusted at goal, n (%) | 1,495 (47.8)‡ | 776 (39.9) | 472 (45.9)# | 230 (43.1) | 234 (44.2) |
*
Abbrev: ACEI, angiotensin-converting-enzyme inhibitor; Thiazide, thiazide and thiazide-like diuretics; β-blocker, beta blockers cardio-selective; ARB, angiotensin II receptor antagonist; CCB, calcium channel blockers.
†
Unadjusted p values were from analysis of variance (ANOVA) or logistic regression while risk-adjusted p values were from analysis of covariance (ANCOVA) or logistic regression.
‡
ACEI vs. Thiazide p <0.001.
§
ACEI vs. CCB p=0.04.
||
ACEI vs. Thiazide p=0.02.
¶
β-blocker vs. Thiazide p=0.003.
#
β-blocker vs. Thiazide p=0.01.